Mayne Pharma ASX SMIDcaps conference presentation
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA ASX SMIDCAPS CONFERENCE
PRESENTATION
25 March 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the
Company) (ASX: MYX), today provides an investor presentation for the ASX SMIDcaps Conference
to be held today in Sydney.
Mayne Pharma’s CEO Mr Aaron Gray will update investors on recent progress across Women’s
Health and Dermatology, and how the Company’s recent DistributeRx launch is supporting
improved access and a more direct pathway from prescription to patient, including Mayne
Pharma’s focus for the remainder of 2026.
The ASX SMIDcaps Conference will take place at:
The Library Auditorium, State Library of NSW, 1 Shakespeare Place, Sydney NSW.
Mayne Pharma’s presentation will be at:
1.25pm AEDT on Wednesday, 25 March 2026
Investors who wish to attend the conference are required to register for the conference as an in-
person participant or on-line at the following link:
https://event.asx.com.au/asxsmidcapsconferencemarch2026
A copy of the presentation is attached.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Board Chair
Email Alerts
To register for an email alert service to receive Mayne Pharma announcements released to the
Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor-
relations/email-alerts/
Follow us on LinkedIn
ASX Announcement
Page 2
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
Mayne Pharma
Group Limited
ASX SMIDCaps Conference
Sydney, Australia
Aaron Gray CEO
25 March 2026
2
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market
disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Non-IFRS information
● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some
non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for
comparison from period to period.
● Earnings before interest, tax, impairment, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings
and performance of the Group and this information may be useful for investors as it provides additional and relevant information that reflects the underlying performance of the
business.
● The non-IFRS financial information has not been audited by the Group’s auditors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which
are outside the control of, and are unknown to the Company. These forward looking statements use words such as ‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other
words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the
Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these
uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under the
listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company’s
future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government
investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of
research and development activities and research collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investor-relations/results-reports and product
descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● ANNOVERA®, BIJUVA®, EPSOLAY®, IMVEXXY®, NEXTSTELLIS®, TWYNEO® are trademarks of third parties.
3
International
Dermatology
A diversified portfolio of branded specialty and generic dermatology medicines
including recently acquired products. Strategy to drive access and lower patient
acquisition costs across rosacea, acne, psoriasis and atopic dermatitis. Strong
focus on channel Disintermediation.
Share price (ASX:MYX) $2.13
Shares on Issue 81.2 million
Market Capitalisation $173.0 million
FY25 Sales $408.1 million
FY25 Underlying EBITDA $47.0 million
Cash & Marketable Securities (31 Dec 2025) $67.4 million
Top 20 Shareholders 63.3%
Substantial Shareholders
Goldman Sachs Group Inc (8.3%)
Mr Bruce Mathieson (6.5%)
UBS Group AG (6.1%)
Rubric Capital Management LP (5.4%)
Analyst Coverage
Madeleine Williams: Canaccord Genuity
Andrew Goodsall: MST Marquee
Snapshot
Corporate Summary1,2
1. Share price data as at 20 March 2026
2. Financial / shareholder data per Mayne Pharma FY25 results, 2025 Annual Report and 1H FY26 results
• Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on
commercialising novel pharmaceuticals, offering patients better, safe and more
accessible medicines in Dermatology and Women’s Health
• Mayne Pharma has a 40-year track record of innovation and success in developing new
oral drug delivery systems. These technologies have been successfully commercialised
in numerous products that continue to be marketed around the world
Our Focus
Segments
Women’s Health
A specialty branded portfolio with significant patent coverage focused on
improving access and adherence in contraception and menopause care
through targeted prescriber engagement and patient support.
Australian-based manufacturer (Salisbury, South Australia) with sales of branded
and generic pharmaceutical products to customers and partners globally (ex-US)
and the provision of contract development and manufacturing services to third
party customers.
Improving patient access to life-enhancing medications
4
$178.4, 44%
$154.1, 38%
$75.6, 18%
FY25 Snapshot - Segments
$109.7m
76% on pcp
FY25 Total Direct Contribution
$62.0, 56%
$40.2, 37%
$7.4, 7%
Women’s Health
FY25 Segment Contribution
($m, % of total)
Dermatology International
FY25 Revenue Contribution
($m, % of total)
5
Global Sales & Headcount
Global footprint
UNITED STATES
$339 million
AUSTRALIA & NEW ZEALAND
$42 million
CANADA
$20 million
EUROPE
$4 million
ASIA
$3 million
T O TA L F Y 2 5 S A L E S
$408.1 million
T O TA L H E A D C O U N T
467
Employees1
1. As at 31 December 2025
6
Mayne Pharma in 2026
FY24 FY25 1H FY26
Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion
68% Branded │ 32% Generic
56% Gross Margin
79% Branded │ 21% Generic
61% Gross Margin
84% Branded │ 16% Generic
65% Gross Margin
500 bps 400 bps
68%
84%
79%
32%
21%
16%
7
Women’s Health: solid portfolio growth
Future growth drivers for Women’s Health
• Drive Market Penetration – increase low single digit market share (versus
competitive set – iQVIA1) + solid market growth
• Strong defence of portfolio economics – long dated patent life to protect value,
support pricing power, and sustain investment through remaining patent life
• Commercial execution – upgraded/refreshed marketing, optimised field-force
effectiveness, and tighter targeting of high-value prescribers/segments
• Improving Access and Coverage – through payer contracting and patient access
programs that reduce friction at the pharmacy counter and drive higher fill rates
• In the past 6 months, Mayne Pharma has entered into agreements which has improved
NEXTSTELLIS® access to approximately 40 million lives in the US
~2%
~1% ~3% ~3%
1. As of Dec 2025; Market share is based on current NRx (new prescription) volume from IQVIA measured against our defined set of competitors per brand.
*Sample US promotional flyer only
8
Dermatology: Improved product mix, solid channel growth from disintermediation strategy
Future growth drivers for Dermatology
• Scale the disintermediation/channel strategy (specialty pharmacy ecosystem) to reduce
friction for prescribers/patients and lift direct contribution as mix improves
• Expand and refresh the dermatology portfolio via capital-efficient, accretive business
arrangements and targeted BD (new FDA-approved brands/products) to broaden
addressable segments
• Drive prescriptions (Rx) through stronger commercial execution—sales force capability
upgrades plus refreshed marketing materials to rebuild/accelerate demand and support
launches.
• Improve gross margin through product mix and channel shift (higher-value brands and
more favourable channel economics) even when top-line is pressured by generics
9
International: investing to create new opportunities
Future growth drivers for International
• More capacity and reliability from Salisbury (post-upgrade) enabling higher
output, better service levels and improved DIFOT1 to support growth in export
and partner demand
• NEXTSTELLIS® PBS listing tailwind driving Australian Rx growth as affordability/
access improves promotion accelerates: 118% growth in 3 pack volumes in Dec
2025 (post PBS) v Jul 2025 (pre PBS)
• Unlock value from significant infrastructure investment (~$18 million), drive
operating leverage and improved utilisation at the facility
• International supply agreements / expanded partnerships to grow exports and
increase third-party volume through the network.
1. DIFOT – Delivered In full on Time
10
Mayne Pharma Disintermediation
1. As a % percentage of total US Women’s Health and Dermatology product volumes
Disintermediation:
Involves removing the intermediaries (wholesalers or others) between the
manufacturer (Mayne Pharma) and the patient
Mayne Pharma US Portfolio 1H FY26
58%
42%
Wholesale Non-Wholesale
17%
83%
Wholesale Non-Wholesale
Women’s Health Dermatology
59%
Non-Wholesale volumes in 1H FY261
11
Disintermediation – What are the benefits?
Patient Benefits
Manufacturer Benefits
Inventory – tighter controls and lower returns
Stronger negotiating position with spec pharmacy v wholesale
Less intermediaries drives lower fees in totality
Transparent and predictable costs
Greater certainty on co-pay arrangements
Higher rates of fulfilment (pharmacy or direct)
Simpler for prescription repeats = higher compliance
Improved Gross to Net Sales
Improved Product Gross Margins
Outcomes for
Mayne Pharma
For example:
12
The US Pharmacy Distribution and Reimbursement System for Patient-
Administered, Outpatient Brand-Name Drugs
GPO= group purchasing organization; PSOA= pharmacy services administrative organization; DIR= direct and indirect remuneration; PBM= pharmacy benefit manager
Source: Drug Channel’s Institute research. Chart illustrates flow for Patient-Administered, Outpatient Drugs. Please note that this chart is illustrative. It is not intended to be a complete representation of every type of product movement, financial
flow, or contractual relationship in the marketplace.
Product movement
Financial flow
Contract relationship
• The path from manufacturer
to patient is complex — and
that complexity has real
consequences.
• Inefficient distribution,
unpredictable pricing, and
significant intermediary
involvement create barriers
at every step of the journey
for manufacturers, clinicians,
and patients alike.
The Problem Manufacturer GPO
Services
contract
Patient
Third-party payer/
Health Plan
Wholesale
% Pass
through of
rebates and
fees
Reimbursement to
PBM (including any
network spread)
PSAO
Negotiation
Services
and
data
fees
(specialty)
Copayment or insurance
Pharmacy
Network participation
Prescription
Reimbursement
Services agreement
Rebates (DIR)
& Fees
Participation
Participation
Prime vendor agreement
Pharmacy payment for product
DIR
Product shipment
Product shipment
Wholesaler payment
for product
Formulary agreement
Dispense prescription
Insurance premiums
13
Mayne Pharma Model to Support Efficiency & Profitability
Manufacturers
Pharmacy
Patients
The Mayne Pharma approach is simple, efficient, and direct:
• Simple — Fewer intermediaries mean clearer pricing for
clinicians and more consistent access to therapy for
patients.
• Efficient — Streamlined distribution reduces friction
across the product lifecycle, improving gross-to-net results
for manufacturers.
• Direct — Medications reach patients faster, with
transparent pricing and fewer delays in care.
The Solution
14
In March 2026 Mayne Pharma Launched the Next Step in the Disintermediation Strategy
DistributeRx partners with manufacturers, providers, and pharmacies
to improve patient access and offer predictable prices.
• Streamlining how therapies move from manufacturer to patient
• Delivering the strategies, tools, and services that ensure patients can start and stay on the therapies
they need
• ePharmacy size ~US$252 billion by 2030 (CAGR 17%) driven by rising consumer adoption of digital
pharmacy and home delivery
PRESCRIPTION ACCESS MADE SIMPLE
15
FY26 focus and outlook
• Women’s Health: continue market share growth with dedicated people who are 100% focused on women’s health, refreshed
marketing, product access solutions, strong intellectual property for our best-in-class products. Targeted investments to drive
growth and sustainable cost leverage.
• Dermatology: take the next step in our disintermediation strategy – fully leverage the ecosystem we have built to improve
access and patient outcomes for dermatology, pursue expansion into other therapeutic areas.
• International: focused activities to unlock the value created by the investments that have been made in the international
business (NEXTSELLIS® PBS listing, capex infusion, international supply agreements).
• Legal: enforce agreements and reserve Mayne Pharma’s rights, balancing costs with shareholder value in mind.
• Capital: acquire synergistic, capital efficient assets to improve scale and capital allocation strategies generally, which may
include a share buy-back.
You deserve tomorrow.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
To register for an email alert service to receive Mayne Pharma announcements released to the
Australian Securities Exchange (ASX) please visit
https://www.maynepharma.com/investor-relations/email-alerts/
Follow us on LinkedIn
Share your feedback
Discover